🏛️ Verified NIH Record • Updated 2025-08-06
Quebec Lung Cancer Screening PLUS Trial (NCT05444062)
Quebec Lung Cancer Screening PLUS Trial - a Randomized Controlled Trial of an Educational Intervention for Untreated Chronic Obstructive Pulmonary Disease (COPD) and/or Cardiovascular Disease (CVD) Identified During Lung Cancer Screening
🔵 Active, Not Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Nicole Ezer, MD, FRCPC, MPH
🩺 Plain-English Summary (8th-Grade Level)
Does an educational intervention for untreated COPD and cardiovascular disease which is integrated in an existing lung cancer screening program improve guideline concordant medication adherence at 12 months
Who can join: Review the eligibility criteria below.
Location: McGill University Health Center — Montreal, Quebec
Age range: 55 Years to 74 Years
🧪 Interventions in This Study
- Educational material and treatment recommendations for patients, general practitioners and pharmacists (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- McGill University Health Center — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COPD
- Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound — Calgary,
- Impairments That Affect Correct Inhaler Use in COPD — Birmingham, Alabama
- The Development of an Integrated Physical Activity and Mental Health Intervention for Veterans With COPD, Emotion Distress, and Low Physical Activity — Boston, Massachusetts
- A Study to Evaluate Solrikitug in Participants With COPD (ZION) — Birmingham, Alabama
- RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD — Calgary, Alberta
- Evaluation of the Safety and Efficacy of TLD in Patients with COPD — Birmingham, Alabama
Explore by condition: All COPD clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.